New Trends in Inflammatory Bowel Disease

Carolina Palmela, Joana Torres, Marilia Cravo*

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

22 Citações (Scopus)

Resumo

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such as vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFα) agents will be available.The future years look promising for IBD. Hopefully the new trends in IBD management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease.

Idioma originalEnglish
Páginas (de-até)103-111
Número de páginas9
RevistaGE Portuguese Journal of Gastroenterology
Volume22
Número de emissão3
DOIs
Estado da publicaçãoPublicado - 2015
Publicado externamenteSim

Impressão digital

Mergulhe nos tópicos de investigação de “New Trends in Inflammatory Bowel Disease“. Em conjunto formam uma impressão digital única.

Citação